# Non-inferiority of GSK Biologicals' DTPw-HBV/Hib Compared to Two Formulations of GSK Biologicals' DTPw-HBV/Hib

> **NCT00473668** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 300 (actual)

## Conditions studied

- Whole Cell Pertussis
- Haemophilus Influenzae Type b
- Tetanus
- Diphtheria
- Hepatitis B

## Interventions

- **BIOLOGICAL:** Zilbrix-Hib
- **BIOLOGICAL:** Tritanrix™-HepB/ Hiberix™

## Key facts

- **NCT ID:** NCT00473668
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06-01
- **Primary completion:** 2008-01-30
- **Final completion:** 2008-01-30
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2017-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00473668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00473668, "Non-inferiority of GSK Biologicals' DTPw-HBV/Hib Compared to Two Formulations of GSK Biologicals' DTPw-HBV/Hib". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00473668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*